Results 61 to 70 of about 1,543,950 (339)

Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination.

JAMA cardiology, 2021
Importance Vaccine-associated myocarditis is an unusual entity that has been described for the smallpox vaccine, but only anecdotal case reports have been described for other vaccines.
Han W. Kim, Elizabeth R Jenista, Dave Wendell, C. Azevedo, M. J. Campbell, S. Darty, M. Parker, R. Kim   +7 more
semanticscholar   +1 more source

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Nature Network Boston, 2021
Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available.
T. Schmidt, V. Klemis, D. Schub, J. Mihm, F. Hielscher, Stefanie Marx, A. Abu-Omar, L. Ziegler, C. Guckelmus, R. Urschel, S. Schneitler, S. Becker, B. Gärtner, U. Sester, M. Sester   +14 more
semanticscholar   +1 more source

Increasing uptake of influenza vaccine by pregnant women post H1N1 pandemic: a longitudinal study in Melbourne, Australia, 2010 to 2014 [PDF]

, 2015
Background: A Melbourne (Australia) university affiliated, tertiary obstetric hospital provides lay and professional education about influenza vaccine in pregnancy annually each March, early in the local influenza season.
McCarthy, Elizabeth Anne, McDonald, Susan, Pollock, Wendy, Sommerville, Maree, Tapper, Lauren   +4 more
core   +3 more sources

Knowledge About the Human Papillomavirus Vaccine Among Employees at a Tertiary Cancer Center: Room for Improvement [PDF]

, 2020
Introduction: The human papillomavirus (HPV) vaccine is recommended by the U.S. Centers for Disease Control and Prevention for routine vaccination of boys and girls to protect against HPV-related cancers and genital warts. To meet the Healthy People 2020
Baum, George P, Bello, Rosalind S, Dahlstrom, Kristina R, DePinho, Ronald A, Hawk, Ernest, Ramondetta, Lois M, Stevens, Lori D, Sturgis, Erich M, Tamez, Elenita   +8 more
core   +2 more sources

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

Nature, 2021
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell responses that continue to evolve for at least a year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to ...
A. Cho, F. Muecksch, Dennis J. Schaefer-Babajew, Zijun Wang, Shlomo Finkin, C. Gaebler, Victor Ramos, M. Cipolla, Pilar Mendoza, Marianna Agudelo, Eva Bednarski, Justin DaSilva, I. Shimeliovich, Juan P Dizon, M. Daga, Katrina G. Millard, Martina Turroja, F. Schmidt, Fengwen Zhang, Tarek Ben Tanfous, M. Jankovic, Thiago Y Oliveria, A. Gazumyan, M. Caskey, P. Bieniasz, T. Hatziioannou, M. Nussenzweig   +26 more
semanticscholar   +1 more source

Comparing methods of assessing dog rabies vaccination coverage in rural and urban communities in Tanzania [PDF]

, 2017
Rabies can be eliminated by achieving comprehensive coverage of 70% of domestic dogs during annual mass vaccination campaigns. Estimates of vaccination coverage are, therefore, required to evaluate and manage mass dog vaccination programs; however, there
Changalucha, Joel, Cleaveland, Sarah, Hampson, Katie, Hotopp, Karen, Johnson, Paul C.D., Kazwala, Rudovick, Lembo, Tiziana, Lugelo, Ahmed, Lushasi, Kennedy, Maziku, Mathew, Mbunda, Eberhard, Mtema, Zacharia, Sambo, Maganga, Sikana, Lwitiko, Townsend, Sunny E.   +14 more
core   +2 more sources

Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2

Frontiers in Immunology, 2023
IntroductionA second generation of prophylactic human papillomavirus (HPV) vaccines based on the minor capsid protein L2 has entered clinical trials as promising alternative to meet the gaps left out by the current vaccines concerning type-restricted ...
Filipe Colaco Mariz, Kerstin Putzker, Peter Sehr, Martin Müller   +3 more
doaj   +1 more source

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis [PDF]

, 2019
Background More than 10 years have elapsed since human papillomavirus (HPV) vaccination was implemented. We did a systematic review and meta-analysis of the population-level impact of vaccinating girls and women against human ...
\uc9lodie, B\ue9nard, A Kahn, Jessica, A Machalek, Dorothy, A Smith, Megan, Ali, Hammad, Baldo, Vincenzo, Boily, MarcMarie\uadClaude, Brassard, Paul, Brisson,, Callander, Denton, Checchi, Marta, Cocchio, Silvia, Dalianis, Tina, Dehlendorff, Christian, Donovan, Basil, F Chow, Eric P, G Pollock, Kevin, Gr\ufcn, Nathalie, Harrison, Christopher, Herweijer, Eva, J Woestenberg, Petra, Jes\ufas Purri\uf1os\uadHermida, Mar\ueda, K Fairley, Christopher, K Kjaer, Susanne, Kavanagh, Kimberley, L Brotherton, Julia M, L Deeks, Shelley, Liu, Bette, M Garland, Suzanne, M Imburgia, Teresa, M Johnson, Anne, M Wheeler, Cosette, M\ue9lanie, Drolet, Markowitz, Lauri, Mesher, David, Munk, Christian, Niccolai, Linda, Norma, P\ue9rez, Nyg\ue5rd, Mari, Ogilvie, Gina, Oliphant, Jeannie, S\uf6derlund\uadStrand, Anna, Sonnenberg, Pam, Sparen, P\ue4r, Steben, Marc, T Hansen, Bo, Tanton, Clare, V Kliewer, Erich, W Flagg, Elaine, W Gargano, Julia, Yu., Bo Nancy   +50 more
core   +2 more sources

Infection Models for Pine Wilt Disease on the Basis of Vector Behaviors

Population Ecology, EarlyView.
Infection models for pine wilt disease without vector density were built to estimate the transmission coefficient of the pathogenic nematode. The models successfully simulated the annual change in the density of infected trees for four pine stands. ABSTRACT Pine wilt disease is caused by the pinewood nematode (Bursaphelenchus xylophilus Steiner et ...
Katsumi Togashi
wiley   +1 more source

Cost-effectiveness of a potential Zika vaccine candidate: a case study for Colombia [PDF]

, 2018
Background: A number of Zika vaccine platforms are currently being investigated, some of which have entered clinical trials. We sought to evaluate the cost-effectiveness of a potential Zika vaccine candidate under the WHO Vaccine Target Product Profile ...
Moghadas, Seyed, Shoukat, Affan, Vilches, Thomas   +2 more
core   +2 more sources